Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
Hypertension (Dallas, Tex. : 1979)
|
September 1, 1981
Plasma concentration and acetylator phenotype determine response to oral hydralazine
A M Shepherd, J L McNay, T M Ludden, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1984
Effect of oral dose size on hydralazine kinetics and vasodepressor response
A M Shepherd, N A Irvine, T M Ludden, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 1, 1983
Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine
M S Lin, J L McNay, A M Shepherd, et al.
Journal of Pharmaceutical Sciences
|
December 1, 1988
Relative bioavailability of immediate- and sustained-release hydralazine formulations
T M Ludden, K S Rotenberg, L K Ludden, et al.
American Journal of Hypertension
|
July 1, 1997
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension
S Oparil, I Kobrin, D R Abernethy, et al.
Plos One
|
March 17, 2021
Yeast grown in continuous culture systems can detect mutagens with improved sensitivity relative to the Ames test
Joseph Y Ong, Julia T Pence, David C Molik, et al.
Research Communications in Chemical Pathology and Pharmacology
|
November 1, 1988
Alpha adrenergic blocking activity of urapidil in man
M J Jamieson, A M Shepherd, S H Jackson, et al.
Journal of Chromatography
|
January 4, 1980
Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine
K D Haegele, H B Skrdlant, T Talseth, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 1, 1979
Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone
T Talseth, K D Haegele, J L McNay, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
July 9, 1998
Thermoregulatory reflexes and cutaneous active vasodilation during heat stress in hypertensive humans
D L Kellogg, S R Morris, S B Rodriguez, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
Hypertension (Dallas, Tex. : 1979)
|
September 1, 1981
Plasma concentration and acetylator phenotype determine response to oral hydralazine
A M Shepherd, J L McNay, T M Ludden, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1984
Effect of oral dose size on hydralazine kinetics and vasodepressor response
A M Shepherd, N A Irvine, T M Ludden, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 1, 1983
Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine
M S Lin, J L McNay, A M Shepherd, et al.
Journal of Pharmaceutical Sciences
|
December 1, 1988
Relative bioavailability of immediate- and sustained-release hydralazine formulations
T M Ludden, K S Rotenberg, L K Ludden, et al.
American Journal of Hypertension
|
July 1, 1997
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension
S Oparil, I Kobrin, D R Abernethy, et al.
Plos One
|
March 17, 2021
Yeast grown in continuous culture systems can detect mutagens with improved sensitivity relative to the Ames test
Joseph Y Ong, Julia T Pence, David C Molik, et al.
Research Communications in Chemical Pathology and Pharmacology
|
November 1, 1988
Alpha adrenergic blocking activity of urapidil in man
M J Jamieson, A M Shepherd, S H Jackson, et al.
Journal of Chromatography
|
January 4, 1980
Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine
K D Haegele, H B Skrdlant, T Talseth, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 1, 1979
Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone
T Talseth, K D Haegele, J L McNay, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
July 9, 1998
Thermoregulatory reflexes and cutaneous active vasodilation during heat stress in hypertensive humans
D L Kellogg, S R Morris, S B Rodriguez, et al.
Page
of 11